146 related articles for article (PubMed ID: 11313891)
21. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells.
Lane D; Cartier A; L'Espérance S; Côté M; Rancourt C; Piché A
Gynecol Oncol; 2004 Jun; 93(3):594-604. PubMed ID: 15196850
[TBL] [Abstract][Full Text] [Related]
22. IG20 (MADD splice variant-5), a proapoptotic protein, interacts with DR4/DR5 and enhances TRAIL-induced apoptosis by increasing recruitment of FADD and caspase-8 to the DISC.
Ramaswamy M; Efimova EV; Martinez O; Mulherkar NU; Singh SP; Prabhakar BS
Oncogene; 2004 Aug; 23(36):6083-94. PubMed ID: 15208670
[TBL] [Abstract][Full Text] [Related]
23. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release.
Röhn TA; Wagenknecht B; Roth W; Naumann U; Gulbins E; Krammer PH; Walczak H; Weller M
Oncogene; 2001 Jul; 20(31):4128-37. PubMed ID: 11464279
[TBL] [Abstract][Full Text] [Related]
24. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma.
Griffith TS; Fialkov JM; Scott DL; Azuhata T; Williams RD; Wall NR; Altieri DC; Sandler AD
Cancer Res; 2002 Jun; 62(11):3093-9. PubMed ID: 12036919
[TBL] [Abstract][Full Text] [Related]
25. Trail-induced apoptosis in Type I leukemic cells is not enhanced by overexpression of bax.
Jia L; Patwari Y; Kelsey SM; Newland AC
Biochem Biophys Res Commun; 2001 May; 283(5):1037-45. PubMed ID: 11355877
[TBL] [Abstract][Full Text] [Related]
26. Bcl-2 oncoprotein protects the human prostatic carcinoma cell line PC3 from TRAIL-mediated apoptosis.
Rokhlin OW; Guseva N; Tagiyev A; Knudson CM; Cohen MB
Oncogene; 2001 May; 20(22):2836-43. PubMed ID: 11420695
[TBL] [Abstract][Full Text] [Related]
27. Complete elimination of colorectal tumor xenograft by combined manganese superoxide dismutase with tumor necrosis factor-related apoptosis-inducing ligand gene virotherapy.
Zhang Y; Gu J; Zhao L; He L; Qian W; Wang J; Wang Y; Qian Q; Qian C; Wu J; Liu XY
Cancer Res; 2006 Apr; 66(8):4291-8. PubMed ID: 16618754
[TBL] [Abstract][Full Text] [Related]
28. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
Ravi R; Bedi A
Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
[TBL] [Abstract][Full Text] [Related]
29. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
Lashinger LM; Zhu K; Williams SA; Shrader M; Dinney CP; McConkey DJ
Cancer Res; 2005 Jun; 65(11):4902-8. PubMed ID: 15930312
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression.
Fulda S; Meyer E; Debatin KM
Oncogene; 2002 Apr; 21(15):2283-94. PubMed ID: 11948412
[TBL] [Abstract][Full Text] [Related]
31. N-(4-hydroxyphenyl) retinamide (4HPR) enhances TRAIL-mediated apoptosis through enhancement of a mitochondrial-dependent amplification loop in ovarian cancer cell lines.
Cuello M; Coats AO; Darko I; Ettenberg SA; Gardner GJ; Nau MM; Liu JR; Birrer MJ; Lipkowitz S
Cell Death Differ; 2004 May; 11(5):527-41. PubMed ID: 14765134
[TBL] [Abstract][Full Text] [Related]
32. Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria.
Zhang XD; Borrow JM; Zhang XY; Nguyen T; Hersey P
Oncogene; 2003 May; 22(19):2869-81. PubMed ID: 12771938
[TBL] [Abstract][Full Text] [Related]
33. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways.
Shankar S; Singh TR; Fandy TE; Luetrakul T; Ross DD; Srivastava RK
Int J Mol Med; 2005 Dec; 16(6):1125-38. PubMed ID: 16273296
[TBL] [Abstract][Full Text] [Related]
34. Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: synergistic action of estrogen metabolite and ligands of death receptor family.
Basu A; Castle VP; Bouziane M; Bhalla K; Haldar S
Cancer Res; 2006 Apr; 66(8):4309-18. PubMed ID: 16618756
[TBL] [Abstract][Full Text] [Related]
35. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
Jazirehi AR; Ng CP; Gan XH; Schiller G; Bonavida B
Clin Cancer Res; 2001 Dec; 7(12):3874-83. PubMed ID: 11751478
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of BAD potentiates sensitivity to tumor necrosis factor-related apoptosis-inducing ligand treatment in the prostatic carcinoma cell line LNCaP.
Taghiyev AF; Guseva NV; Harada H; Knudson CM; Rokhlin OW; Cohen MB
Mol Cancer Res; 2003 May; 1(7):500-7. PubMed ID: 12754297
[TBL] [Abstract][Full Text] [Related]
37. Low extracellular pH augments TRAIL-induced apoptotic death through the mitochondria-mediated caspase signal transduction pathway.
Lee YJ; Song JJ; Kim JH; Kim HR; Song YK
Exp Cell Res; 2004 Feb; 293(1):129-43. PubMed ID: 14729063
[TBL] [Abstract][Full Text] [Related]
38. Hypoxia inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by blocking Bax translocation.
Kim M; Park SY; Pai HS; Kim TH; Billiar TR; Seol DW
Cancer Res; 2004 Jun; 64(12):4078-81. PubMed ID: 15205314
[TBL] [Abstract][Full Text] [Related]
39. Sodium nitroprusside (SNP) sensitizes human gastric cancer cells to TRAIL-induced apoptosis.
Yang L; Lan C; Fang Y; Zhang Y; Wang J; Guo J; Wan S; Yang S; Wang R; Fang D
Int Immunopharmacol; 2013 Oct; 17(2):383-9. PubMed ID: 23871247
[TBL] [Abstract][Full Text] [Related]
40. Low glucose-enhanced TRAIL cytotoxicity is mediated through the ceramide-Akt-FLIP pathway.
Nam SY; Amoscato AA; Lee YJ
Oncogene; 2002 Jan; 21(3):337-46. PubMed ID: 11821946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
